Astrana Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Astrana Health, Inc. (Nasdaq: ASTH) on June 10, 2026. The report details the outcomes of the Company's 2026 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and maintains its principal executive offices in Alhambra, California.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and equity plan matters.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved the Amended and Restated 2024 Equity Incentive Plan. The number of shares reserved for issuance was increased by 1,000,000 shares, and the plan term was extended to March 24, 2036.
- Board Elections: Nine directors were elected to serve until the 2027 Annual Meeting. All nominees received majority support.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: The compensation program for named executive officers was approved on an advisory, non-binding basis.
Voting Results and Shareholder Participation
As of the record date (April 14, 2026), there were 55,713,532 shares of common stock outstanding. At the Annual Meeting, 43,772,595 shares were present in person or by proxy, representing approximately 78.6% of eligible votes.
| Proposal | For Votes | Against/Withheld | Abstain |
|---|---|---|---|
| Election of Directors (Aggregate) | 300,605,893 | 16,042,360 | N/A |
| Ratification of Auditors | 43,722,509 | 19,566 | 30,520 |
| Advisory Vote on Compensation | 34,119,199 | 1,209,072 | 88,206 |
| Approval of 2024 Equity Plan | 34,679,879 | 701,303 | 35,295 |
Guidance, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond standard corporate governance disclosures. No unusual items were reported.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the amended 2024 Equity Incentive Plan to assess potential future dilution.
- Review the full text of the Amended and Restated 2024 Equity Incentive Plan filed as Exhibit 10.1 for specific vesting terms and eligibility criteria.
- Confirm the composition of the newly elected Board of Directors and their tenure through the 2027 Annual Meeting.
- Note that the filing does not contain updated financial statements; refer to the most recent 10-K or 10-Q for financial health metrics.